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Abstract
According to the current point of view described in the literature, the transcription fac‐
tor aryl hydrocarbon receptor nuclear translocator (ARNT), also designated as hypoxia‐
inducible factor (HIF)‐1β, is constitutively expressed and not influenced by oxygen 
tension. However, a study published two decades ago provided early evidence regarding 
a hypoxia‐dependent ARNT upregulation. This finding was subsequently challenged and 
neglected. Until now, only a limited number of publications focus on the regulation of 
ARNT in hypoxia. Therefore, appropriate studies and the putative mechanism mediating 
this cellular attribute are discussed. The advantages of an elevated ARNT expression level 
in tumour cells are delineated. This chapter provides an overview of hypoxia‐inducible 
ARNT as an emerging concept in HIF biology.
Keywords: aryl hydrocarbon receptor nuclear translocator, ARNT, HIF‐1β, crosstalk, 
cancer
1. Introduction
The name aryl hydrocarbon receptor nuclear translocator (ARNT) designates a transcrip‐
tion factor of the Per‐ARNT‐Sim family which is ubiquitously expressed. This protein is also 
known as hypoxia‐inducible factor (HIF)‐1β. The use of these two equal synonyms for the 
same transcription factor throughout the literature already implies its role in various signal‐
ling pathways [1]. Unfortunately, the term “hypoxia‐inducible” might be misleading in this 
context. According to the current point of view described in the literature, ARNT expression is 
not affected by environmental conditions such as hypoxia. Therefore, ARNT is considered to 
be a constitutively expressed gene [1]. Although this notion might be true for the majority of 
cells/tissues investigated, numerous studies reported the capability of tumour cells to elevate 
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ARNT expression in response to hypoxia [1–7]. This cellular attribute was found in cells of 
different tumour types of both human and murine origin. These key findings clearly suggest 
that hypoxia‐dependent ARNT upregulation might provide a certain benefit for appropriate 
cells [1].
ARNT and its paralogue ARNT2 [1] share a 90% identical amino acid sequence [8]. In contrast 
to ARNT, ARNT2 is mainly expressed in the central nervous system [8, 9]. ARNT2 expression 
was shown to be positively correlated with breast cancer prognosis [8]. In addition, high‐
ARNT2 levels in hepatocellular carcinomas are associated with a prolonged overall survival 
of cancer patients [8]. However, many functions of this transcription factor are still unknown 
[1, 8]. Moreover, the regulation of ARNT and ARNT2 varied in human hepatocellular carci‐
noma Hep3B cells. ARNT was elevated in hypoxia, whereas ARNT2 was not affected in this 
model [3].
This chapter describes the current knowledge regarding hypoxic upregulation of ARNT, 
which appears to be beneficial for certain types of tumour cells. Therefore, the aim of this 
section is to emphasise this unique cellular attribute. A potential altered ARNT expression 
level due to hypoxic exposure of cells should be considered and not generally excluded. In 
this context, the use of ARNT as loading control or as a reference gene is basically not recom‐
mended [1].
2. Regulation of ARNT
2.1. Upregulation of ARNT in response to hypoxia
First evidence for a hypoxia‐dependent regulation of ARNT was provided by Wang et al. [5]. 
Herein, Hep3B cells were used to study the effects of HIF‐1α and ARNT under hypoxic condi‐
tions. ARNT was elevated on mRNA level in this cell line due to hypoxic exposure (1% v/v O
2
). 
In addition, treatment with hypoxia mimetics such as cobalt chloride and desferrioxamine had 
similar effects. Nuclear extracts prepared from Hep3B and HeLa cells were used to investigate 
the response of both HIF‐1 subunits to oxygen deprivation. Re‐oxygenation experiments were 
also included into the study [5]. The data revealed that both transcription factors HIF‐1α and 
ARNT were inducible in hypoxic cells on mRNA as well as protein levels [5]. Huang et al. [10] 
reported that ARNT protein levels remained constant regardless of cellular oxygen tension. 
In this study, Hep3B, HeLa and HEK293 cells were used. Unfortunately, not all experiments 
were conducted with all cell lines [10], thereby making a direct comparison with the study of 
Wang et al. [5] complicated. Nevertheless, the latter report [10] challenged the results of the 
previous one [5] due to signal variations of Northern blots and discontinuities of time‐course 
experiments [10].
However, Huang et al. [10] proposed a very graphic working model including a specific sensor 
for hypoxia located in the cell membrane [10]. The depicted mechanism is similar to our nowa‐
days HIF scheme. These days the prolylhydroxylase domain enzymes (PHDs), which require 
O
2
 as a substrate, are known to act as cellular oxygen sensors [11]. The comparison of both 
seminal studies conducted by Wang et al. [5] and Huang et al. [10] also requires a glance on 
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citation frequencies of both reports. Noteworthily, the report of Wang et al. [5], which describes 
the upregulation of ARNT for the first time, was cited approximately four times more often as 
compared to Huang et al. [10]. Despite this clear distinction of citation frequencies, the opinion 
that ARNT is unaffected by cellular oxygen tension became a guideline in HIF biology [1].
The capability to elevate ARNT expression in hypoxia was also found in murine L929 and 
Hepa1 cells. Interestingly, human Hep3B cells were also used in this study conducted by 
Chilov et al. [7], but ARNT was unaffected by oxygen deprivation [7]. This seemingly con‐
flicting observation compared to a previous report [5] is likely due to different experimental 
conditions. Obviously, a short‐term exposure of Hep3B cells to hypoxia (4 h in Ref. [7]) is not 
sufficient to induce ARNT protein expression in this model. However, other studies clearly 
confirmed the hypoxia‐dependent upregulation of ARNT in Hep3B cells [3, 4].
First mechanistic clues regarding the induction of ARNT under oxygen deprivation were 
provided by Zhong et al. [6]. Herein, the authors tested the hypothesis whether HIF‐1α and 
ARNT are regulated by similar signalling pathways in human prostate cancer cells. Indeed, 
an elevated ARNT protein level was observed in hypoxic PC‐3 cells. Interestingly, this effect 
was attenuated by inhibition of the phosphatidylinositol‐3 kinase (PI3K)/AKT‐pathway by 
Wortmannin [6]. Another hint regarding the ARNT expression pattern in cancer cells came 
from Skinner et al. [12]. Herein, the authors investigated the transcriptional regulation of 
VEGF in ovarian cancer cell lines in response to PI3K/Akt signalling. Blocking of this path‐
way using the compound LY294002 specifically inhibited HIF‐1α expression but had no 
effect on ARNT. Unfortunately, the inducibility of ARNT in hypoxia was not tested in this 
study [12]. Most important, the observation that PI3K/Akt inhibition decreased HIF‐1α but 
not ARNT in one model [12] whereas both transcription factors were reduced on protein 
level in another model [6] might suggest a HIF‐dependent regulation of ARNT in certain 
cell lines.
The studies discussed so far clearly show that certain cell lines are capable to induce ARNT 
in hypoxia and that this effect is dependent on the experimental conditions (i.e. time points). 
Thus, one might assume that scientists became more aware of this phenomenon over time. 
However, ARNT was also used as a loading control in Western blot analysis [12, 13]. This 
application clearly demonstrates the major opinion of a complete non‐hypoxic regulation of 
ARNT. Of note, effects of hypoxia and hypoxia mimetics on ARNT expression should be 
taken into consideration when studying the HIF pathway as previously proposed [1]. Such 
an approach will help to identify new cell types harbouring the hypoxia‐inducible ARNT 
attribute and might provide novel mechanistic insights. The current proposed mechanism is 
discussed later in the chapter.
The seminal study conducted by Choi et al. shed light on ARNT expression and turnover [14]. 
The authors assumed that the regulation of ARNT expression or activity might significantly 
affect cell metabolism. Thus, ARNT should be regarded as a drug target and appropriate 
compounds need to be investigated. De novo synthesis of ARNT, enhanced stability of the 
protein and dimerisation with HIF‐1α, represents three ways how this transcription factor can 
be controlled. Curcumin, the major component of the spice turmeric, was tested in this study 
for potential inhibitory effects on HIF‐1. Interestingly, curcumin facilitated the degradation 
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of ARNT and blocked HIF signalling [14]. Similar effects were reported by Ströfer et al. [15]. 
Curcumin‐mediated ARNT depletion was observed in human HepG2, Hep3B and MCF‐7 
cells [15]. The half‐life of ARNT was determined in Hep3B cells after cycloheximide treat‐
ment and calculated with approximately 5 h [14]. In contrast, curcumin exposure decreased 
ARNT half‐life to roughly 2 h. It turned out that the curcumin‐dependent degradation of 
ARNT was redox sensitive and could be reversed by antioxidants and the proteasome inhibi‐
tor MG‐132 [14]. Remarkably, MG‐132 did not affect ARNT protein level in the absence of cur‐
cumin. Therefore, the authors proposed the existence of two different mechanisms mediating 
ARNT turnover: a proteasome‐independent mechanism under physiological conditions and 
a proteasome‐dependent degradation in response to stress [14].
The elevation of ARNT protein expression under oxygen deprivation might not be an exclu‐
sive trait of cell lines. Exposure of primary mouse keratinocytes to acute hypoxia (1% O
2
) 
resulted in an upregulation of ARNT after 4 and 5 h, respectively [16]. However, this effect was 
not statistically significant. Putative alterations on ARNT mRNA expression were also evalu‐
ated in this cell model. In contrast, time‐course experiments revealed no apparent changes 
on mRNA level in murine keratinocytes cultured in hypoxia up to 48 h [16]. The selection of 
an inappropriate internal control in qPCR analysis can also lead to different expression lev‐
els in normoxia and hypoxia [17]. Therefore, Vavilala et al. determined the expression level 
of three housekeeping genes (ribosomal protein L32, β‐actin and GAPDH) in normoxic and 
hypoxic cells, respectively [17]. The authors observed no significant changes on mRNA levels 
between both experimental settings. The aim of this study was to investigate inhibitory effects 
of Honokiol, a biphenolic phytochemical compound, on HIF signalling in several cell lines. 
The results presented in this report consist solely of gene expression data. Among them, the 
HIF‐1α, HIF‐2α and ARNT mRNA level were compared under normoxic and hypoxic condi‐
tions [17]. Remarkably, an approximately 7‐fold increase in ARNT mRNA was observed in 
D407 human retinal pigment epithelial cells. In addition, a 2‐fold upregulation was detected 
in HT‐29 cells and a slight increase in the HEK293 cell line. MCF‐7 cells showed no increase in 
ARNT mRNA due to hypoxic exposure. Unfortunately, the comparison of these effects among 
the cell lines tested in this study is limited because of different time points used (12 versus 24 h 
in D407 cells; 1% O
2
) [17]. Nevertheless, the study provides clear evidence of a cell‐specific 
transcriptional ARNT upregulation in hypoxia although these findings were not confirmed 
by Western blotting.
Further mechanistic insights into this cellular trait were provided by a research project inves‐
tigating the regulation of ARNT in human melanoma cells [2]. Among a panel of five different 
cell lines, ARNT was rapidly elevated on protein level in 518A2 cells after treatment with 
the hypoxia mimetic cobalt chloride (CoCl
2
). Interestingly, knockdown of HIF‐1α in CoCl
2
 
stimulated and hypoxic 518A2 cells abolished the hypoxia‐dependent upregulation of ARNT. 
Overexpression of a dominant‐negative HIF mutant in this cell model indicated that ARNT 
expression is dependent on the HIF pathway itself. In agreement with these findings, overex‐
pression of HIF‐1α caused an elevation of ARNT protein in CoCl
2
 treated 518A2 cells. Taken 
together, this study demonstrated a regulatory relationship between HIF‐1α and its binding 
partner ARNT for the first time. In addition, it was concluded that this capability might pre‐
vent ARNT to become a limiting factor in hypoxia [2].
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The first comprehensive study aiming to re‐evaluate the regulation of ARNT was conducted 
by Wolff et al. [4]. Herein, numerous cell lines were exposed to 1 and 3% O
2
 for different time 
points. In addition, hypoxia mimetics such as CoCl
2
 and dimethyloxalylglycine (DMOG) were 
used and the quantity of ARNT protein determined by Western blotting. The authors found 
out that ARNT expression was induced in MCF‐7, HeLa and Hep3B cells. Interestingly, the 
ARNT level was also dependent on the hypoxic environment used. A concentration of 1% 
O
2
 led to a faster increase in ARNT protein but also to an earlier decline to basal levels as 
compared to 3% hypoxia. Moreover, the appropriate mRNA levels did not correlate with the 
amount of protein detected. In particular, in MCF‐7 and Hep3B cells, a downregulation of 
ARNT mRNA was observed due to hypoxia. Therefore, the authors hypothesised the existence 
of a reciprocal feedback regulation between ARNT protein stability and de novo synthesis. 
This study provides convincing evidence that the predominant point of view that ARNT is 
unaffected by hypoxia and hypoxia mimetics cannot be applied to all cell lines in general [4].
The first review highlighting the topic of hypoxia‐inducible ARNT was published by Mandl 
and Depping [1]. Herein, two major questions were raised: (1) How can cells acquire this attri‐
bute? and (2) What is the benefit for these cells? [1] Both issues will be discussed below. An 
updated list of cell lines capable to elevate ARNT in response to hypoxia is presented in Table 1. 
Among them, the human Hep3B cell line is obviously the best studied model in this context.
2.1.1. Purpose of hypoxia‐inducible ARNT
The capability of certain tumour cells to upregulate ARNT under hypoxic conditions might 
provide a specific survival advantage as previously proposed [1]. Indeed, we recently discov‐
ered a relationship between ARNT and the cellular response to radiation [18]. Tumour hypoxia 
Cell line Species Origin References
518A2 Human Melanoma [2]
A375 Human Melanoma [2]
D407 * Human Retinal pigment epithelium [17]
HEK‐293* Human Embryonic kidney [17]
HeLa Human Cervix adenocarcinoma [4]
Hep3B Human Hepatoma [3–5]
Hepa1 Mouse Hepatoma [7]
HT‐29* Human Colorectal adenocarcinoma [17]
L929 Mouse Connective tissue [7]
LNCaP* Human Prostate cancer [20]
MCF‐7 Human Breast carcinoma [4]
PC‐3 Human Prostate cancer [20, 6]
*Only shown on mRNA level.
Table 1. Cell lines with hypoxia‐inducible ARNT expression.
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is associated with radioresistance and poor patient prognosis. Therefore, we investigated 
the effects of an altered expression of ARNT on radioresistance and performed clonogenic 
survival assays. As expected, silencing of ARNT in Hep3B and MCF‐7 cells by siRNA ren‐
dered these models susceptible to radiation. Interestingly, overexpression of ARNT in these 
cell lines promoted radioresistance. Therefore, it was hypothesised that radiation treatment 
might provide a selection pressure and lead to an enrichment of high‐ARNT expressing cells. 
Taken together, these findings provide evidence to consider ARNT as a drug target in order 
to increase radiosensitivity in tumour cells and as a predictive marker in this context [18].
As outlined above, there is evidence that HIF‐1α mediates the elevation of ARNT under hypoxic 
conditions in certain cell lines. This regulatory relationship is the prerequisite of a feed‐forward 
loop (FFL) as demonstrated recently in Hep3B cells. In such a network motif, one transcription 
factor regulates the other and both controls the expression of a target gene cooperatively. Given 
the fact that HIF‐1α and ARNT form the transcriptional active complex HIF‐1, which regulates 
a plethora of target genes, the FFL definition is fulfilled. By using reporter gene assays, we were 
able to demonstrate that overexpression of ARNT in Hep3B cells increased the luciferase signal 
in hypoxia. Therefore, it was concluded that augmented HIF signalling in terms of elevated 
target gene expression might be beneficial for tumour cells. These findings support the concept 
of ARNT being a limiting factor in at least certain cell models [3].
Moreover, general considerations regarding inducible gene expression are in line with the 
studies discussed above. In order to respond rapidly to micro‐environmental alterations 
required genes need to be specifically activated. Inducible genes are highly regulated and 
must be quickly shut down to basal expression levels once the stimulus disappeared [19].
2.1.2. Mechanism of hypoxia‐dependent ARNT upregulation
The mechanism(s) underlying this unique cellular attribute is (are) unclear. There is mount‐
ing evidence indicating a pivotal role of HIF‐1α [2–4]. It was demonstrated that ARNT was 
increased in 518A2 human melanoma cells in a HIF‐1α‐dependent manner under hypoxic 
conditions [2]. A very similar mechanism was revealed in Hep3B cells [3]. Knockdown and 
overexpression of HIF‐1α affected the ARNT protein level accordingly. Moreover, a clear tran‐
scriptional relationship between HIF‐1α and its binding partner ARNT was established in this 
model system. Treatment with actinomycin D, an inhibitor of RNA synthesis, diminished the 
induction of ARNT under oxygen deprivation. In addition, appropriate gene‐silencing experi‐
ments and qRT‐PCR analysis confirmed this finding [3]. Another important observation might 
designate HIF‐1α as a mediator of this cellular attribute. The PI3K/Akt inhibitor LY294002 was 
shown to inhibit HIF‐1α expression in ovarian cancer cell lines but had no effect on ARNT 
protein [12]. In contrast, several independent studies have shown that the hypoxia‐dependent 
increase in ARNT was abolished by blocking the PI3K/Akt pathway with LY294002 or similar 
compounds [2, 6, 20]. This finding—the susceptibility of ARNT to PI3K/Akt inhibition in certain 
models—might be characteristic for cells capable to induce ARNT in hypoxia. Taken together, 
this suggests a linear model and might imply ARNT to be a downstream target of HIF‐1α.
The cellular cause of the regulatory relationship between HIF‐1α and ARNT is not known. 
HIF‐1α can act independent of its binding partner ARNT and regulate gene expression [1]. 
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It was shown that HIF‐1α can act as a co‐activator or co‐repressor on certain genes. In addi‐
tion, an indirect regulatory connection between both transcription factors might exist [1]. 
HIF‐regulated genes encode for growth factors, glucose transporters, glycolytic enzymes but 
also other transcription factors and miRNAs. Therefore, HIF‐controlled transcription fac‐
tors and miRNAs might influence ARNT expression [1, 3]. A general working concept is 
discussed below.
2.1.2.1. Working concept of hypoxia‐inducible ARNT
Based on the studies mentioned above, a general working concept can be deduced (Figure 1). 
In addition to its oxygen regulation, the HIF pathway, that is, HIF‐1α, is also controlled by 
growth factors via the PI3K/Akt signalling cascade leading to elevated translation [21, 22]. 
Upon activation HIF‐1α induces the upregulation of its binding partner ARNT either on 
mRNA and/or protein level in appropriate cell lines. For instance, it was shown that hypoxic 
induction of ARNT in Hep3B cells is mediated by de novo synthesis [3]. This effect can be 
achieved either directly or indirectly. A direct mechanism might involve the recruitment of 
HIF‐1α to the ARNT promoter, whereas an indirect mechanism might be mediated by other 
HIF‐regulated transcription factors or miRNAs [1]. Indeed, a complex mutual regulatory rela‐
tionship between miRNAs and PAS proteins exists. However, the physiological and patho‐
physiological mechanisms behind are unclear [23].
Figure 1. General working concept of hypoxia‐inducible ARNT. See text for details.
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Our recent experiments revealed that HIF‐1α and ARNT are recruited to the ARNT gene 
promoter in hypoxic Hep3B cells. Deployment of CRISPR/Cas9 gene editing technology con‐
firmed the importance of a unique genomic sequence for hypoxia‐dependent ARNT upreg‐
ulation. Therefore, these findings suggest a direct mechanism and render ARNT a putative 
HIF‐1 target gene in Hep3B cells (unpublished observations; manuscript in preparation).
The regulatory relationship between HIF‐1α and ARNT is part of a feed‐forward loop 
(FFL; Figure 1: red arrows) as already demonstrated in Hep3B cells [3]. Subsequently, HIF‐1α 
and its binding partner ARNT form the transcriptional active heterodimer HIF‐1 and initiate 
the expression of various target genes. Therefore, an increased target gene expression seems 
to be beneficial for tumour cells [3].
2.1.3. Experimental conditions
Although the hypoxic inducibility of ARNT is described in specific cell lines by convincing 
data, not every study could confirm this circumstance. This obvious conflict depends mainly 
on the experimental conditions used. For instance, it was demonstrated that in Hep3B cells, 
3% O
2
 for 8 h was sufficient to elevate ARNT on protein level [3]. In contrast, a peak induction 
on mRNA level was observed after 5 h in the same setting [3]. Of note, these conditions need 
not to be appropriate in other cells. Until now, a few studies reported that ARNT mRNA and 
protein levels do not correlate in a number of cell lines [4, 18].
2.2. Regulation of ARNT by other factors
The regulation of ARNT or whether it responds to stimulation is poorly understood. There 
is evidence that ARNT expression is controlled by the NF‐κB pathway in different models. It 
was demonstrated that ARNT mRNA was induced in HEK293 cells due to TNF‐α stimula‐
tion. This effect was abrogated by pharmacological blocking or silencing of the NF‐κB cascade 
[24]. Moreover, Per‐ARNT‐Sim (PAS) transcription factors belonging to different signalling 
circuits can compete for common binding partners such as ARNT (discussed below). Thus, 
misregulation of these proteins might contribute to tumour survival [9]. Noteworthily, the 
mutual regulation of PAS transcription factors on mRNA level was also mentioned in the 
literature, but appropriate citations are missing [22].
3. Crosstalk between Per‐ARNT‐Sim transcription factors
The HIF, AhR and BMAL1/Clock pathways respond to a decline in cellular oxygen concentra‐
tion, environmental xenobiotics or govern circadian rhythms, respectively. All of these tran‐
scription factors are related. They belong to the group of Per‐ARNT‐Sim (PAS) transcription 
factors which are characterised by the presence of a PAS domain (composed of PAS‐A and 
PAS‐B subdomains) required for protein‐protein interactions. Therefore, all family members 
are able to form homo‐ and heterodimers among the group [9, 25].
The transcription factor ARNT plays a pivotal role within the HIF and AhR pathways. It serves 
as the common binding partner for HIF‐α subunits and ligands activated AhR proteins [1]. 
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Therefore, a competition between both signalling cascades regarding the recruitment of 
ARNT might be obvious. Indeed, early evidence for such an antagonism was provided by 
Gradin et al. [26]. By using luciferase reporter gene constructs under the control of xenobi‐
otic‐responsive elements (XRE), the effect of HIF and AhR activation was studied in HepG2 
cells. As expected, stimulation of cells with an appropriate AhR ligand leads to a pronounced 
induction of reporter gene expression. This effect was suppressed by co‐treatment with the 
hypoxia mimetic cobalt chloride. Co‐immunoprecipitation experiments clearly indicated a 
competition between the HIF and AhR pathway relating to ARNT binding. In addition, it was 
shown that HIF‐1α could efficiently compete with the AhR for dimerisation with ARNT. This 
study provided evidence for a HIF‐1α‐mediated inhibition of AhR signalling by sequestra‐
tion of ARNT [26]. Vorrink et al. [27] observed similar effects again in human hepatocellular 
carcinoma HepG2 cells and in the human keratinocyte HaCaT cell line. One major advantage 
of this study was the genuine hypoxic exposure of cells instead of stimulation with hypoxia 
mimetics such as cobalt chloride. AhR signalling was triggered by treatment with the dioxin‐
like compound PCB126. Again, hypoxia inhibited CYP1A1 reporter gene activity in PCB126 
stimulated HepG2 cells. Importantly, ARNT overexpression caused an elevated luminescence 
signal under normoxic and hypoxic conditions. Moreover, forced ARNT expression was suf‐
ficient to overcome the inhibitory effect of hypoxia on AhR signalling. The authors concluded 
that ARNT is sequestered by HIF‐1α in hypoxia thus limiting the availability of this transcrip‐
tion factor for AhR heterodimerisation [27]. Noteworthily, another report published nearly 
two decades ago claims the complete opposite [28]. This study might provide evidence for 
a lack of competition between HIF and AhR signalling on ARNT recruitment. Unfortunately, 
the presented arguments and data are not convincing at many points [28].
Furthermore, a crosstalk between AhR and BMAL1/Clock exists. Lipophilic AhR ligands such 
as dioxin or dietary polyphenols bind within the AhR PAS‐B domain and trigger nuclear trans‐
location. Within the nucleus activated AhR can dimerise with BMAL1 thus disrupting the auto‐
regulatory loop of BMAL1/Clock genes. Therefore, AhR activation leads to a suppression of 
circadian rhythms, whereas AhR inhibition strengthens rhythm amplitude [25]. Interestingly, 
there is evidence that both AhR and ARNT are expressed in an oscillatory pattern in vivo [29].
4. Subcellular dynamics of ARNT and turnover
Translocation of ARNT from the cytoplasm into the nucleus is mediated by importins as also 
demonstrated for other HIF family members [30, 31]. Blocking of this specific process was 
proposed as a novel way to suppress HIF signalling [30]. Whether ARNT shuttles, back into 
the cytoplasm is unknown. Under these circumstances, inhibition of the putative nuclear 
export might prolong HIF activity. Moreover, whether ARNT is degraded, within the nucleus 
is not investigated in greater depth (depicted in Figure 2).
In general, there is evidence for two different mechanisms leading to ARNT degradation. 
It was found out that ARNT was not affected by the proteasome inhibitor MG‐132 under 
physiological conditions. In contrast, proteasomal degradation of ARNT might be triggered 
by reactive oxygen species [3, 14].
Hypoxic Upregulation of ARNT (HIF-1β): A Cell-Specific Attribute with Clinical Implications
http://dx.doi.org/10.5772/67171
39
5. Clinical aspects
Inhibition of the HIF pathway is proposed as a treatment strategy in oncology. Several appro‐
priate compounds have been identified and confirmed in xenograft models. These drugs are 
able to block different processes of the HIF signalling pathway. For instance, HIF‐1α protein 
synthesis is diminished by rapamycin which is an inhibitor of mTOR. The antibiotic acrifla‐
vine prevents heterodimerisation of HIF‐1α and ARNT subunits [32]. Moreover, a plethora of 
other HIF inhibitors was discovered which comprise of different chemical entities. HIF is con‐
sidered as an attractive drug target, and blocking of its activity might lead to cytostatic anti‐
tumour effects. A synergistic outcome with radiotherapy is also expected [33, 34]. However, 
such drugs might be useful in multidrug regimes only in a subset of cancer patients. Cancers 
in which HIF is a strong driving force for disease progression are assumed to be susceptible 
for anti‐HIF treatment [32].
The temporal importance of ARNT during tumour growth was investigated by Shi et al. 
[35]. Herein, the authors used murine hepatoma Hepa‐1 cells transduced with a Tet‐Off 
mArnt construct. Xenograft experiments conducted with these cells indicated that ARNT 
is particularly required during the early stage of tumour growth. The authors proposed 
that a profound inhibition of the HIF pathway might be achieved only by suppressing 
both HIF‐1α and HIF‐2α proteins. Therefore, it was concluded that the binding partner 
ARNT might represent a preferable therapeutic target rather than HIF‐α subunits [35]. 
More convincing evidence regarding the role of ARNT in this malignancy was provided 
by a study using human tissue samples and cell lines [36]. ARNT expression was analysed 
by immunohistochemistry in hepatocellular carcinoma (HCC) and liver tissues. ARNT 
Figure 2. Subcellular logistics of ARNT. See text for details.
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was found primarily in the nucleus but also in the cytoplasm in a minor fraction of cells. 
Interestingly, ARNT expression was significantly higher in normal liver samples as com‐
pared to appropriate HCC tissues. In addition, the impact of ARNT expression on overall 
survival (OS) of HCC patients was evaluated [36]. Surprisingly, a high intra‐tumour ARNT 
level was associated with a prolonged OS. In agreement with this observation, stably len‐
tiviral transduced ARNT‐knockdown HCCLM6 cells showed a high proliferation rate, 
whereas overexpression of ARNT had the opposite effect. In addition, ARNT‐suppressed 
cells formed smaller tumours in a murine xenograft model as compared to appropriate 
ARNT‐overexpressing counterparts. This finding is in line with clinical data indicating a 
smaller tumour size in high‐ARNT expressing hepatocellular carcinoma [36]. Moreover, 
the incidence of recurrence after surgery was significantly lower when a high intra‐tumour 
ARNT level was detected. Taken together, this study describes an inhibitory role of ARNT 
in HCC progression. It was concluded that ARNT is a central regulator in HCC progres‐
sion and a useful predictive marker regarding curative resection. The authors proposed 
that the relative balance of ARNT and its binding partners might be an important determi‐
nant in HCC [36]. In addition, another study demonstrated an important role of ARNT in 
this malignancy. Choi et al. [37] silenced ARNT expression in several human hepatoma cell 
lines by using siRNA and evaluated the effects on cell growth. It was shown that knock‐
down of this transcription factor inhibited proliferation and sensitised cells to apoptosis 
[37]. An elegant approach to target ARNT by small molecule inhibitors was conducted by 
Guo et al. [38]. Herein, nuclear magnetic resonance and biochemical screens were used 
in order to identify molecules selectively binding to the PAS domain of ARNT. The com‐
pound KG‐548 was discovered to compete with the co‐activator TACC3 for ARNT binding. 
The specific blocking of protein‐protein interactions among transcription factors repre‐
sents a novel technique to inhibit HIF signalling. Due to the shared use of ARNT among 
alpha subunits, targeting this protein was proposed to be more efficient as compared to 
its counterparts [38]. Evidence highlighting the importance of ARNT as a drug target was 
also provided by another study. Chan and colleagues [39] described that ARNT expression 
enhances cisplatin resistance in cancer cells. This phenotype was mediated by upregula‐
tion of MDR1, a multidrug efflux pump of the ABC superfamily, by a direct mechanism. 
Accordingly, knockdown of ARNT by siRNA transfection reduced cisplatin resistance in 
human cancer cells. Moreover, ARNT silencing increased the therapeutic efficacy of this 
cytotoxic drug in a murine xenograft model [39].
Targeting the HIF pathway in cancer therapy in order to achieve tumour control has been pro‐
posed by several reports [40–42]. Remarkably, the majority of HIF inhibitors described until 
now lack specificity. For instance, the drug topotecan blocks topoisomerase I activity but also 
diminished HIF signalling in preclinical models. This inhibitory effect on HIF was accom‐
plished by preventing the accumulation of HIF‐1α. In multihistology target‐driven clinical 
trial, Kummar et al. [43] evaluated the oral use of this compound in a small number of cancer 
patients. Different tumour entities were diagnosed in these patients including ovarian cancer, 
sarcoma and melanoma among others. A complete inhibition of HIF‐1α was detected in biop‐
sies of a few patients, but inherent sampling and heterogeneous HIF‐1α expression might 
limit this finding [43]. In contrast, despite the clear role of ARNT in tumour progression, its 
drug‐ability and appropriate treatment effects need to be evaluated in a clinical setting.
Hypoxic Upregulation of ARNT (HIF-1β): A Cell-Specific Attribute with Clinical Implications
http://dx.doi.org/10.5772/67171
41
6. Concluding remarks
The attribute of certain tumour cells to elevate the transcription factor ARNT in hypoxia was 
shown decades ago but since neglected in HIF biology. Only a small number of studies focus 
on the regulation of ARNT, especially under hypoxic conditions. Therefore, hypoxia‐induc‐
ible ARNT is an emerging concept in this field. According to the major opinion, ARNT is a 
constitutively expressed gene. This means that ARNT expression is not effected by environ‐
mental factors such as hypoxia. Due to the fact that there are exceptions from this dogma, the 
statement of a constitutive ARNT expression should be revised and not used in general terms. 
Thus, ARNT should be regarded as a “cell‐specific facultative gene” in tumour cells which 
indicates an expression as needed.
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